IDEAYA Biosciences, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
IDEAYA's registrational OptimUM-02 trial of darovasertib + crizotinib met its primary endpoint in 313 HLA*A2:01-negative metastatic uveal melanoma patients, showing median PFS of 6.9 months vs. 3.1 months (HR 0.42, p=0.0001). In June 2026, IDEAYA raised $323.4M net from equity offering (7.2M shares + 5.6M pre-funded warrants) and $33.1M from at-the-market offering, bringing cash to $1.24B with runway into 2030 unchanged. NDA filing underway under real-time oncology review with H2 2026 target completion.
Why this rating
Major primary endpoint win in lead program + substantial capital raise (18% of market cap) funds multi-year pipeline. High execution risk on commercialization remains.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.